

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DINGDANG HEALTH TECHNOLOGY GROUP LTD.
叮噹健康科技集團有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 09886)

VOLUNTARY ANNOUNCEMENT
VOLUNTARY LOCK-UP UNDERTAKINGS MADE BY
CONTROLLING SHAREHOLDERS GROUP

This announcement is made by Dingdang Health Technology Group Ltd. (the “**Company**”) on a voluntary basis.

Reference is made to (i) the prospectus of the Company dated September 1, 2022 (the “**Prospectus**”) and (ii) the allotment results announcement of the Company dated September 13, 2022, in relation to, among others, the lock-up undertaking (the “**First Lock-up Undertaking**”) of a total of 660,205,360 shares of the Company (the “**Relevant Share(s)**”) controlled by the group of Controlling Shareholders (as defined in the Prospectus) of the Company (the “**Controlling Shareholders Group**”). Unless otherwise defined, terms used in this announcement shall have the same meaning as those defined in the Prospectus.

According to the First Lock-up Undertaking, the Controlling Shareholders Group will not, unless in compliance with the requirements of the Listing Rules,

- (i) in the period (the “**First Lock-up Period**”) from the date of the Prospectus and ending on March 13, 2023 (inclusive, being the date which is six months from the Listing Date), dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Relevant Shares; or
- (ii) in the period of six months (the “**Second Lock-up Period**”) commencing on the date on which the First Lock-up Period expires, dispose of, or enter into any agreement to dispose of or otherwise create, any options, rights, interests or encumbrances in respect of, any of the Relevant Shares to such an extent that immediately following such disposal, or upon the exercise or enforcement of such options, rights, interests or encumbrances, he or it would cease to be a group of controlling shareholders (as defined in the Listing Rules) of the Company.

For further details of such lock-up undertaking by the Controlling Shareholders Group, please refer to the section headed “Underwriting” in the Prospectus.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces that, the Company has been advised by the Controlling Shareholders Group that, in order to demonstrate their faith in the long-term value and future prospects of long-term development of the Company and without any prejudice to the First Lock-up Undertaking, each of them has made a voluntary undertaking (the “**Second Lock-up Undertaking**”, together with the First Lock-up Undertaking referred to as the “**Lock-up Undertakings**”) to the Company to extend the First Lock-up Period till September 13, 2023 (inclusive), during which they will not dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Relevant Shares. Accordingly, the Second Lock-up Period will commence on September 14, 2023 (inclusive) and end on March 13, 2024 (inclusive), during which the Controlling Shareholders Group will not dispose of, or enter into any agreement to dispose of or otherwise create, any options, rights, interests or encumbrances in respect of, any of the Relevant Shares to such an extent that immediately following such disposal, or upon the exercise or enforcement of such options, rights, interests or encumbrances, he or it would cease to be a group of controlling shareholders (as defined in the Listing Rules) of the Company.

As at the date of this announcement, the total number of the Relevant Shares is 660,205,360, representing approximately 49.21% of the total issued shares of the Company. Details of the lock-up arrangement as contemplated under the Lock-up Undertakings are as follows:

	Number of the Relevant Shares as at the date of this announcement	Approximate percentage of shareholding of the Relevant Shares held in the total issued shares of the Company as at the date of this announcement	Last day subject to the Lock-up Undertakings
Delight Health Limited ⁽¹⁾	276,712,555	20.62%	September 13, 2023 (First Lock-up Period) and March 13, 2024 (Second Lock-up Period)
Excel Returns Group Limited ⁽²⁾	11,760,000	0.88%	September 13, 2023 (First Lock-up Period) and March 13, 2024 (Second Lock-up Period)
Future Health Limited ⁽³⁾	295,499,475	22.02%	September 13, 2023 (First Lock-up Period) and March 13, 2024 (Second Lock-up Period)
Go Prosper Enterprises Corporation ⁽⁴⁾	54,400,000	4.06%	September 13, 2023 (First Lock-up Period) and March 13, 2024 (Second Lock-up Period)
Much Premium Investment Limited ⁽⁴⁾	21,833,330	1.63%	September 13, 2023 (First Lock-up Period) and March 13, 2024 (Second Lock-up Period)
Total	660,205,360	49.21%	

Notes:

- (1) As at the date of this announcement, Delight Health Limited is wholly owned by Delight Faith Limited; Delight Faith Limited is owned by Mr. Yang Wenlong, a Director and controlling shareholder of the Company, as to 60% of its equity interests and Mr. Yang Yibin as to 40% of its equity interests.
- (2) As at the date of this announcement, Excel Returns Group Limited is wholly owned by Delight Faith Limited.
- (3) As at the date of this announcement, Future Health Limited is wholly owned by Go Far Limited; Go Far Limited is owned by Mr. Yang Wenlong as to 60% of its equity interests and Mr. Yang Xiao as to 40% of its equity interests.
- (4) Go Prosper Enterprises Corporation and Much Premium Investment Limited are the platforms of the Restricted Share Scheme, which are wholly-owned by participants of the Restricted Share Scheme. Participants of the Restricted Share Scheme irrevocably delegated the voting rights in the Company held or to be held by them to Mr. Yang Wenlong or such other person(s) as designated by Mr. Yang Wenlong.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
DINGDANG HEALTH TECHNOLOGY GROUP LTD.
YANG WENLONG
Chairman

Hong Kong, March 12, 2023

As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei and Mr. YU Qinglong, the non-executive Directors are Ms. CAI Li and Ms. LIAN Suping, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Mr. FAN Zhenhong and Mr. JIANG Shan.